RCS - Angle PLC - Parsortix and assays being showcased at EACR 2024

AngleAnnouncement

11/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240611:nRSK8660Ra&default-theme=true

RNS Number : 8660R  Angle PLC  11 June 2024

 For immediate release  11 June 2024

 

ANGLE plc ("the Company")

 

PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT the 2024 Annual Congress of the
European Association for Cancer Research

 

ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual
analysis and ANGLE's DNA Damage Response assay

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce its participation at
the 2024 Annual Congress of the European Association for Cancer Research (EACR
2024) being held in Rotterdam, Netherlands from 10 to 13 June 2024.

 

ANGLE is presenting two posters at EACR 2024:

 

1.  Targeted sequencing of circulating tumour cells captured by the Parsortix
system enables low frequency variant analysis with pan-cancer Next Generation
Sequencing (NGS) panel

 

The dual analysis of CTCs and circulating tumour DNA (ctDNA) is emerging as a
workflow to provide a more comprehensive analysis of a patient's cancer*. In
this presentation CTC-DNA obtained from Parsortix enriched CTCs and ctDNA from
matched plasma samples from 10 ovarian, 13 breast, and 14 lung cancer patients
were evaluated. Mutation profiles were reported using targeted NGS performed
on the Illumina NextSeq 2000 platform.

 

In all three cancer types, higher percentages of mutations were identified
exclusively in CTCs as compared to ctDNA. Mutations were co-detected in CTC
and ctDNA at a frequency of 61%, 30% and 34% for samples from ovarian, breast
and lung cancer patients respectively, demonstrating that both complementary
and additional information can be obtained when investigating both sample
types concurrently.

 

This presentation highlights the value of profiling CTCs using the Parsortix
system in addition to ctDNA analysis, to better report on genetic
heterogeneity. The dual analysis of CTCs and ctDNA holds potential to guide
personalised treatment selection and therapeutic monitoring towards improving
the cancer patient care pathway.

 

2.  Detection of DNA damage in CTCs harvested from blood samples of ovarian
and prostate cancer patients

 

Gamma H2AX (γ-H2AX) and Phospho KAP1 (pKAP1) are biomarkers used to identify
the activation of the DNA damage response (DDR) pathway. Monitoring this
activation can be important when evaluating the effectiveness of cancer
therapies that target the DDR pathway. ANGLE has developed a DDR assay* for
the assessment of these biomarkers in CTCs harvested using the Parsortix
system.

 

This poster presentation reports on the performance of ANGLE's
immunofluorescence assay for the identification of different CTC phenotypes
(epithelial, mesenchymal and those transitioning) and the determination of DDR
status (γ-H2AX or pKAP1). Analytical verification reported that the assay
successfully produced linear data, with high analytical sensitivity(1) and
analytical specificity(2) of ≥90% for epithelial, mesenchymal, blood lineage
and DDR markers.

 

The presentation also reported that in samples from ovarian and prostate
cancer patients, CTCs were found in 93% of patients overall; and in 62% of
ovarian and 77% of prostate cancer patient samples one or more DDR positive
CTCs were identified. This data demonstrates the feasibility of using the
Parsortix system in combination with ANGLE's DDR assay to monitor CTC count
and DDR status as a method of real-time treatment assessment.

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"We are delighted to have had two posters presented at the EACR 2024. The
results of these studies further demonstrate the utility of ANGLE's technology
for dual analysis of CTC-DNA and ctDNA and the utility of ANGLE's DDR assay.
These solutions are at the forefront of cancer research, and we look forward
to discussions with translational researchers and industry partners at this
event."

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

*For Research Use Only. Not for use in diagnostic procedures.

 

1.   Analytical sensitivity = proportion of harvested cells known to express
the marker(s) of interest which were marker positive in the assay.

2.   Analytical specificity = proportion of harvested cells known to NOT
express the marker(s) of interest which were marker negative in the assay.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix(®)
PC1 system enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK. Services include custom made assay
development and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAKKEFLKLEFA